日本麻疹疫苗的研发。

Development of measles vaccines in Japan.

作者信息

Ueda Shigeharu

机构信息

The Research Foundation for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.

出版信息

Vaccine. 2009 May 21;27(24):3230-1. doi: 10.1016/j.vaccine.2009.02.066. Epub 2009 Feb 28.

DOI:10.1016/j.vaccine.2009.02.066

PMID:19446197

Abstract

Studies on measles vaccine development started in 1950s in Japan. After 3-year studies on development of further attenuated live measles vaccines by Japan Measles Vaccine Research Commission, two kinds of vaccines of different strains were licensed for optional use in 1971. In 1978, periodical immunization against measles was started using BIKEN CAM-70 vaccine, Takeda Schwarz-FF8 vaccine and Kitasato AIK-C vaccine. Combined measles and rubella vaccines (MR vaccine) were licensed in 2005. Periodical immunization with MR vaccines of BIKEN and Takeda Pharmaceutical Co. Ltd. to eliminate measles together with rubella from Japan by 2012 was started for children 1- and 6 (5-7)-year of age in 2006.

摘要

麻疹疫苗的研发工作于20世纪50年代在日本启动。日本麻疹疫苗研究委员会对进一步减毒活麻疹疫苗进行了3年的研发研究后，两种不同毒株的疫苗于1971年获得许可可供选择使用。1978年，开始使用比肯CAM - 70疫苗、武田施瓦茨 - FF8疫苗和北里AIK - C疫苗进行麻疹定期免疫接种。麻疹风疹联合疫苗（MR疫苗）于2005年获得许可。2006年，针对1岁和6（5 - 7）岁儿童开始使用比肯和武田制药有限公司的MR疫苗进行定期免疫接种，以期到2012年在日本消除麻疹和风疹。